Galectin-3 binding protein secreted by breast cancer cells inhibits monocyte-derived fibrocyte differentiation

Journal of Immunology

Volumn 195, Issue 4, 2015, Pages 1858-1867

  White, Michael J V ^a   Roife, David ^b   Gomer, Richard H ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD209 ANTIGEN; GALECTIN 1; GALECTIN 3; GALECTIN 3 BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 3; MESSENGER RNA; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CULTURE MEDIUM; DC-SPECIFIC ICAM-3 GRABBING NONINTEGRIN; GLYCOPROTEIN; LECTIN; LGALS3BP PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL ADHESION; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL SURVIVAL; CELLS BY BODY ANATOMY; CELLULAR SECRETION; CONTROLLED STUDY; CULTURE MEDIUM; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNNODEPLETION; IMMUNOLOGICAL PROCEDURES; MDA MB 231 CELL LINE; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MONOCYTE DERIVED FIBROCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SPLEEN CELL; TUMOR MICROENVIRONMENT; WILD TYPE; ANIMAL; BREAST TUMOR; CYTOLOGY; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MONOCYTE; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARRIER PROTEINS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FEMALE; GALECTIN 1; GALECTIN 3; GLYCOPROTEINS; HUMANS; LECTINS, C-TYPE; MICE; MONOCYTES; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84938945261     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500365     Document Type: Article

References (125)

1. Hamilton, J. A. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8: 533-544.
2. Murray, P. J., and T. A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11: 723-737.
3. Abe, R., S. C. Donnelly, T. Peng, R. Bucala, and C. N. Metz. 2001. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166: 7556-7562.
4. Bucala, R., L. A. Spiegel, J. Chesney, M. Hogan, and A. Cerami. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1: 71-81.
5. White, M. J., E. D. Galvis-Carvajal, and R. H. Gomer. 2015. A brief exposure to tryptase or thrombin potentiates fibrocyte differentiation in the presence of serum or serum amyloid p. J. Immunol. 194: 142-150.
6. Suko, T., I. Ichimiya, K. Yoshida, M. Suzuki, and G. Mogi. 2000. Classification and culture of spiral ligament fibrocytes from mice. Hear. Res. 140: 137-144.
7. Strieter, R. M., E. C. Keeley, M. A. Hughes, M. D. Burdick, and B. Mehrad. 2009. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol. 86: 1111-1118.
8. Pilling, D., T. Fan, D. Huang, B. Kaul, and R. H. Gomer. 2009. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 4: e7475.
9. Bellini, A., and S. Mattoli. 2007. The role of the fibrocyte, a bone marrowderived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87: 858-870.
10. Paget, J. 1853. Lectures on Surgical Pathology Delivered at the Royal College of Surgeons of England. Wilson and Ogilvy, London.
11. Mattoli, S., A. Bellini, and M. Schmidt. 2009. The role of a human hematopoietic mesenchymal progenitor in wound healing and fibrotic diseases and implications for therapy. Curr. Stem Cell Res. Ther. 4: 266-280.
12. Bellini, A., M. A. Marini, L. Bianchetti, M. Barczyk, M. Schmidt, and S. Mattoli. 2012. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol. 5: 140-149.
13. Isgrò, M., L. Bianchetti, M. A. Marini, A. Bellini, M. Schmidt, and S. Mattoli. 2013. The C-C motif chemokine ligands CCL5, CCL11, and CCL24 induce the migration of circulating fibrocytes from patients with severe asthma. Mucosal Immunol. 6: 718-727.
14. Bianchetti, L., M. A. Marini, M. Isgrò, A. Bellini, M. Schmidt, and S. Mattoli. 2012. IL-33 promotes the migration and proliferation of circulating fibrocytes from patients with allergen-exacerbated asthma. Biochem. Biophys. Res. Commun. 426: 116-121.
15. Pilling, D., C. D. Buckley, M. Salmon, and R. H. Gomer. 2003. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 171: 5537-5546.
16. Pilling, D., V. Vakil, and R. H. Gomer. 2009. Improved serum-free culture conditions for the differentiation of human and murine fibrocytes. J. Immunol. Methods 351: 62-70.
17. Reilkoff, R. A., R. Bucala, and E. L. Herzog. 2011. Fibrocytes: emerging effector cells in chronic inflammation. Nat. Rev. Immunol. 11: 427-435.
18. Moeller, A., S. E. Gilpin, K. Ask, G. Cox, D. Cook, J. Gauldie, P. J. Margetts, L. Farkas, J. Dobranowski, C. Boylan, et al. 2009. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179: 588-594.
19. Quan, T. E., S. E. Cowper, and R. Bucala. 2006. The role of circulating fibrocytes in fibrosis. Curr. Rheumatol. Rep. 8: 145-150.
20. Strieter, R. M., E. C. Keeley, M. D. Burdick, and B. Mehrad. 2009. The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans. Am. Clin. Climatol. Assoc. 120: 49-59.
21. Pilling, D., D. Roife, M. Wang, S. D. Ronkainen, J. R. Crawford, E. L. Travis, and R. H. Gomer. 2007. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J. Immunol. 179: 4035-4044.
22. Naik-Mathuria, B., D. Pilling, J. R. Crawford, A. N. Gay, C. W. Smith, R. H. Gomer, and O. O. Olutoye. 2008. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. 16: 266-273.
23. Herzog, E. L., and R. Bucala. 2010. Fibrocytes in health and disease. Exp. Hematol. 38: 548-556.
24. Andrade, Z. A. 2009. Schistosomiasis and liver fibrosis. Parasite Immunol. 31: 656-663.
25. Boros, D. L. 1989. Immunopathology of Schistosoma mansoni infection. Clin. Microbiol. Rev. 2: 250-269.
26. Wahl, S. M., M. Frazier-Jessen, W. W. Jin, J. B. Kopp, A. Sher, and A. W. Cheever. 1997. Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney Int. 51: 1370-1375.
27. Wyler, D. J., S. M. Wahl, and L. M. Wahl. 1978. Hepatic fibrosis in schistosomiasis: egg granulomas secrete fibroblast stimulating factor in vitro. Science 202: 438-440.
28. Schedin, P., and A. Elias. 2004. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 6: 93-101.
29. Kim, B. G., H. J. An, S. Kang, Y. P. Choi, M. Q. Gao, H. Park, and N. H. Cho. 2011. Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer. Am. J. Pathol. 178: 373-381.
30. Coulson-Thomas, V. J., Y. M. Coulson-Thomas, T. F. Gesteira, C. A. de Paula, A. M. Mader, J. Waisberg, M. A. Pinhal, A. Friedl, L. Toma, and H. B. Nader. 2011. Colorectal cancer desmoplastic reaction up-regulates collagen synthesis and restricts cancer cell invasion. Cell Tissue Res. 346: 223-236.
31. Cichon, M. A., A. C. Degnim, D. W. Visscher, and D. C. Radisky. 2010. Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J. Mammary Gland Biol. Neoplasia 15: 389-397.
32. Shao, Z. M., M. Nguyen, and S. H. Barsky. 2000. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345.
33. Walker, R. A. 2001. The complexities of breast cancer desmoplasia. Breast Cancer Res. 3: 143-145.
34. Coulson-Thomas, V. J., Y. M. Coulson-Thomas, T. F. Gesteira, C. A. de Paula, A. M. Mader, J. Waisberg, M. A. Pinhal, A. Friedl, L. Toma, and H. B. Nader. 2011. Colorectal cancer desmoplastic reaction up-regulates collagen synthesis and restricts cancer cell invasion. Cell Tissue Res. 346: 223-236.
35. Finn, O. J. 2012. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23(Suppl. 8): viii6-viii9.
36. Gajewski, T. F., H. Schreiber, and Y. X. Fu. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14: 1014-1022.
37. Solito, S., L. Pinton, V. Damuzzo, and S. Mandruzzato. 2012. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol. Invest. 41: 722-737.
38. Biragyn, A., and D. L. Longo. 2012. Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses. Semin. Cancer Biol. 22: 50-59.
39. Lakshmi Narendra, B., K. Eshvendar Reddy, S. Shantikumar, and S. Ramakrishna. 2013. Immune system: a double-edged sword in cancer. Inflamm. Res. 62: 823-834.
40. Cailleau, R., R. Young, M. Olivé, and W. J. Reeves, Jr. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53: 661-674.
41. Abdelkarim, M., N. Vintonenko, A. Starzec, A. Robles, J. Aubert, M. L. Martin, S. Mourah, M. P. Podgorniak, S. Rodrigues-Ferreira, C. Nahmias, et al. 2011. Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype. PLoS One 6: e23334.
42. Koths, K., E. Taylor, R. Halenbeck, C. Casipit, and A.Wang. 1993. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 268: 14245-14249.
43. Ullrich, A., I. Sures, M. D'Egidio, B. Jallal, T. J. Powell, R. Herbst, A. Dreps, M. Azam, M. Rubinstein, C. Natoli, et al. 1994. The secreted tumor-associated antigen 90K is a potent immune stimulator. J. Biol. Chem. 269: 18401-18407.
44. Nonaka, M., B. Y. Ma, H. Imaeda, K. Kawabe, N. Kawasaki, K. Hodohara, N. Kawasaki, A. Andoh, Y. Fujiyama, and T. Kawasaki. 2011. Dendritic cellspecific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J. Biol. Chem. 286: 22403-22413.
45. Resnick, D., A. Pearson, and M. Krieger. 1994. The SRCR superfamily: a family reminiscent of the Ig superfamily. Trends Biochem. Sci. 19: 5-8.
46. D'Ostilio, N., G. Sabatino, C. Natoli, A. Ullrich, and S. Iacobelli. 1996. 90K (Mac-2 BP) in human milk. Clin. Exp. Immunol. 104: 543-546.
47. Iacobelli, S., E. Arnò , A. D'Orazio, and G. Coletti. 1986. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res. 46: 3005-3010.
48. Wang, Y., X. Ao, H. Vuong, M. Konanur, F. R. Miller, S. Goodison, and D. M. Lubman. 2008. Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J. Proteome Res. 7: 4313-4325.
49. Mbeunkui, F., B. J. Metge, L. A. Shevde, and L. K. Pannell. 2007. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J. Proteome Res. 6: 2993-3002.
50. Grassadonia, A., N. Tinari, I. Iurisci, E. Piccolo, A. Cumashi, P. Innominato, M. D'Egidio, C. Natoli, M. Piantelli, and S. Iacobelli. 2004. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 19: 551-556.
51. Tinari, N., R. Lattanzio, P. Querzoli, C. Natoli, A. Grassadonia, S. Alberti, M. Hubalek, D. Reimer, I. Nenci, P. Bruzzi, et al. 2009. High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. Int. J. Cancer 124: 333-338.
52. Iacobelli, S., P. Sismondi, M. Giai, M. D'Egidio, N. Tinari, C. Amatetti, P. Di Stefano, and C. Natoli. 1994. Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer 69: 172-176.
53. Hughes, R. C. 1999. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim. Biophys. Acta 1473: 172-185.
54. Piccolo, E., N. Tinari, D. Semeraro, S. Traini, I. Fichera, A. Cumashi, R. La Sorda, F. Spinella, A. Bagnato, R. Lattanzio, et al. 2013. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J. Mol. Med. 91: 83-94.
55. Trahey, M., and I. L. Weissman. 1999. Cyclophilin C-associated protein: a normal secreted glycoprotein that down-modulates endotoxin and proinflammatory responses in vivo. Proc. Natl. Acad. Sci. USA 96: 3006-3011.
56. Moutsatsos, I. K., M. Wade, M. Schindler, and J. L. Wang. 1987. Endogenous lectins from cultured cells: nuclear localization of carbohydrate-binding protein 35 in proliferating 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA 84: 6452-6456.
57. Hughes, R. C. 1997. The galectin family of mammalian carbohydrate-binding molecules. Biochem. Soc. Trans. 25: 1194-1198.
58. Xu, X. C., A. K. el-Naggar, and R. Lotan. 1995. Differential expression of galectin-1 and galectin-3 in thyroid tumors: potential diagnostic implications. Am. J. Pathol. 147: 815-822.
59. Coli, A., G. Bigotti, F. Zucchetti, F. Negro, and G. Massi. 2002. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 40: 80-87.
60. Gruson, D., and G. Ko. 2012. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin. Biochem. 45: 719-726.
61. McCullough, P. A., A. Olobatoke, and T. E. Vanhecke. 2011. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev. Cardiovasc. Med. 12: 200-210.
62. Sundblad, V., D. O. Croci, and G. A. Rabinovich. 2011. Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol. Histopathol. 26: 247-265.
63. Krzeslak, A., and A. Lipinska. 2004. Galectin-3 as a multifunctional protein. Cell. Mol. Biol. Lett. 9: 305-328.
64. Cox, N., D. Pilling, and R. H. Gomer. 2012. NaCl potentiates human fibrocyte differentiation. PLoS One 7: e45674.
65. White, M. J., M. Glenn, and R. H. Gomer. 2013. Trypsin potentiates human fibrocyte differentiation. PLoS One 8: e70795.
66. Cailleau, R., M. Olivé, and Q. V. Cruciger. 1978. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915.
67. Miller, F. R., S. J. Santner, L. Tait, and P. J. Dawson. 2000. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst. 92: 1185-1186.
68. von Kleist, S., E. Chany, P. Burtin, M. King, and J. Fogh. 1975. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J. Natl. Cancer Inst. 55: 555-560.
69. Leibovitz, A., J. C. Stinson, W. B. McCombs, III, C. E. McCoy, K. C. Mazur, and N. D. Mabry. 1976. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569.
70. Shirasawa, S., M. Furuse, N. Yokoyama, and T. Sasazuki. 1993. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88.
71. Dexter, D. L., J. A. Barbosa, and P. Calabresi. 1979. N,N-Dimethylformamideinduced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells. Cancer Res. 39: 1020-1025.
72. Soule, H. D., J. Vazguez, A. Long, S. Albert, and M. Brennan. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51: 1409-1416.
73. Scudiero, D. A., A. Monks, and E. A. Sausville. 1998. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J. Natl. Cancer Inst. 90: 862.
74. Hamilton, T. C., R. C. Young, W. M. McKoy, K. R. Grotzinger, J. A. Green, E. W. Chu, J. Whang-Peng, A. M. Rogan, W. R. Green, and R. F. Ozols. 1983. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389.
75. Hamilton, T. C., R. C. Young, and R. F. Ozols. 1984. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298.
76. Park, J. G., J. H. Lee, M. S. Kang, K. J. Park, Y. M. Jeon, H. J. Lee, H. S. Kwon, H. S. Park, K. S. Yeo, K. U. Lee, et al. 1995. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282.
77. Aden, D. P., A. Fogel, S. Plotkin, I. Damjanov, and B. B. Knowles. 1979. Controlled synthesis of HBsAg in a differentiated human liver carcinomaderived cell line. Nature 282: 615-616.
78. Fogh, J., J. M. Fogh, and T. Orfeo. 1977. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226.
79. Pontén, J., and E. H. Macintyre. 1968. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 74: 465-486.
80. Lieber, M., J. Mazzetta, W. Nelson-Rees, M. Kaplan, and G. Todaro. 1975. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int. J. Cancer 15: 741-747.
81. Steube, K. G., D. Teepe, C. Meyer, M. Zaborski, and H. G. Drexler. 1997. A model system in haematology and immunology: the human monocytic cell line MONO-MAC-1. Leuk. Res. 21: 327-335.
82. Ziegler-Heitbrock, H. W., E. Thiel, A. Fütterer, V. Herzog, A. Wirtz, and G. Riethmüller. 1988. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41: 456-461.
83. Sundström, C., and K. Nilsson. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577.
84. Collins, S. J., R. C. Gallo, and R. E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270: 347-349.
85. Tsuchiya, S., M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno, and K. Tada. 1980. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer 26: 171-176.
86. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59-74.
87. Rae, J. M., C. J. Creighton, J. M. Meck, B. R. Haddad, and M. D. Johnson. 2007. MDA-MB-435 cells are derived from M14 melanoma cells-A loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 104: 13-19.
88. Buckley, C. D., D. Pilling, N. V. Henriquez, G. Parsonage, K. Threlfall, D. Scheel-Toellner, D. L. Simmons, A. N. Akbar, J. M. Lord, and M. Salmon. 1999. RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397: 534-539.
89. Salmon, M., D. Scheel-Toellner, A. P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A. D. D'Angeac, P. A. Bacon, P. Emery, and A. N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99: 439-446.
90. UniProt Consortium. 2014. Activities at the Universal Protein Resource (Uni-Prot). Nucleic Acids Res. 42: D191-D198.
91. Lanoue, A., M. R. Clatworthy, P. Smith, S. Green, M. J. Townsend, H. E. Jolin, K. G. Smith, P. G. Fallon, and A. N. McKenzie. 2004. SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J. Exp. Med. 200: 1383-1393.
92. Crawford, J. R., D. Pilling, and R. H. Gomer. 2010. Improved serum-free culture conditions for spleen-derived murine fibrocytes. J. Immunol. Methods 363: 9-20.
93. Endo, H., T. Muramatsu, M. Furuta, N. Uzawa, A. Pimkhaokham, T. Amagasa, J. Inazawa, and K. Kozaki. 2013. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis 34: 560-569.
94. Bullwinkel, J., A. Ludemann, J. Debarry, and P. B. Singh. 2011. Epigenotype switching at the CD14 and CD209 genes during differentiation of human monocytes to dendritic cells. Epigenetics 6: 45-51.
95. Anthony, R. M., F. Wermeling, M. C. Karlsson, and J. V. Ravetch. 2008. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105: 19571-19578.
96. Anthony, R. M., and J. V. Ravetch. 2010. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30 (Suppl. 1): S9-S14.
97. Inohara, H., S. Akahani, K. Koths, and A. Raz. 1996. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56: 4530-4534.
98. Iurisci, I., N. Tinari, C. Natoli, D. Angelucci, E. Cianchetti, and S. Iacobelli. 2000. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 6: 1389-1393.
99. Kohatsu, L., D. K. Hsu, A. G. Jegalian, F. T. Liu, and L. G. Baum. 2006. Galectin-3 induces death of Candida species expressing specific b-1,2-linked mannans. J. Immunol. 177: 4718-4726.
100. Iurisci, I., A. Cumashi, A. A. Sherman, Y. E. Tsvetkov, N. Tinari, E. Piccolo, M. D'Egidio, V. Adamo, C. Natoli, G. A. Rabinovich, et al. 2009. Synthetic inhibitors of galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res. 29: 403-410.
101. Sasaki, T., C. Brakebusch, J. Engel, and R. Timpl. 1998. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds b1 integrins, collagens and fibronectin. EMBO J. 17: 1606-1613.
102. Blake, J. A., C. J. Bult, J. T. Eppig, J. A. Kadin, and J. E. Richardson, Mouse Genome Database Group. 2014. The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse. Nucleic Acids Res. 42: D810-D817.
103. Whelan, S. A., J. He, M. Lu, P. Souda, R. E. Saxton, K. F. Faull, J. P. Whitelegge, and H. R. Chang. 2012. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid. J. Proteome Res. 11: 5034-5045.
104. Lawlor, K., A. Nazarian, L. Lacomis, P. Tempst, and J. Villanueva. 2009. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 8: 1489-1503.
105. Kulasingam, V., and E. P. Diamandis. 2008. Tissue culture-based breast cancer biomarker discovery platform. Int. J. Cancer 123: 2007-2012.
106. Pavlou, M. P., and E. P. Diamandis. 2010. The cancer cell secretome: a good source for discovering biomarkers? J. Proteomics 73: 1896-1906.
107. Colzani, M., P. Waridel, J. Laurent, E. Faes, C. Rüegg, and M. Quadroni. 2009. Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. J. Proteome Res. 8: 4779-4788.
108. Palazzolo, G., N. N. Albanese, G. DI Cara, D. Gygax, M. L. Vittorelli, and I. Pucci-Minafra. 2012. Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res. 32: 847-860.
109. Zhang, Y., X. Tang, L. Yao, K. Chen, W. Jia, X. Hu, and L. X. Xu. 2012. Lectin capture strategy for effective analysis of cell secretome. Proteomics 12: 32-36.
110. Ross, D. T., U. Scherf, M. B. Eisen, C. M. Perou, C. Rees, P. Spellman, V. Iyer, S. S. Jeffrey, M. Van de Rijn, M. Waltham, et al. 2000. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24: 227-235.
111. Cesinaro, A. M., C. Natoli, A. Grassadonia, N. Tinari, S. Iacobelli, and G. P. Trentini. 2002. Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. J. Invest. Dermatol. 119: 187-190.
112. He, J., S. A. Whelan, M. Lu, D. Shen, D. U. Chung, R. E. Saxton, K. F. Faull, J. P. Whitelegge, and H. R. Chang. 2011. Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response. Int. J. Proteomics 2011: 896476.
113. Kostianets, O., S. Antoniuk, V. Filonenko, and R. Kiyamova. 2012. Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas. Diagn. Pathol. 7: 161.
114. Lee, J. H., X. Zhang, B. K. Shin, E. S. Lee, and I. Kim. 2009. Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study. Pathology 41: 229-233.
115. Iacobelli, S., I. Bucci, M. D'Egidio, C. Giuliani, C. Natoli, N. Tinari, M. Rubistein, and J. Schlessinger. 1993. Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines. FEBS Lett. 319: 59-65.
116. Scambia, G., P. B. Panici, G. Baiocchi, L. Perrone, S. Iacobelli, and S. Mancuso. 1988. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res. 8: 761-764.
117. Gortzak-Uzan, L., A. Ignatchenko, A. I. Evangelou, M. Agochiya, K. A. Brown, P. St. Onge, I. Kireeva, G. Schmitt-Ulms, T. J. Brown, J. Murphy, et al. 2008. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J. Proteome Res. 7: 339-351.
118. Inohara, H., and A. Raz. 1994. Identification of human melanoma cellular and secreted ligands for galectin-3. Biochem. Biophys. Res. Commun. 201: 1366-1375.
119. Traini, S., E. Piccolo, N. Tinari, C. Rossi, R. La Sorda, F. Spinella, A. Bagnato, R. Lattanzio, M. D'Egidio, A. Di Risio, et al. 2014. Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. Mol. Cancer Ther. 13: 916-925.
120. Morandi, F., M. V. Corrias, I. Levreri, P. Scaruffi, L. Raffaghello, B. Carlini, P. Bocca, I. Prigione, S. Stigliani, L. Amoroso, et al. 2011. Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunol. Immunother. 60: 1485-1495.
121. Chen, S. T., T. L. Pan, H. F. Juan, T. Y. Chen, Y. S. Lin, and C. M. Huang. 2008. Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J. Proteome Res. 7: 1379-1387.
122. Liu, F. T., D. K. Hsu, R. I. Zuberi, I. Kuwabara, E. Y. Chi, and W. R. Henderson, Jr. 1995. Expression and function of galectin-3, a b-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 147: 1016-1028.
123. Grandin, E. W., P. Jarolim, S. A. Murphy, L. Ritterova, C. P. Cannon, E. Braunwald, and D. A. Morrow. 2012. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin. Chem. 58: 267-273.
124. Traber, P. G., and E. Zomer. 2013. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 8: e83481.
125. Traber, P. G., H. Chou, E. Zomer, F. Hong, A. Klyosov, M. I. Fiel, and S. L. Friedman. 2013. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 8: e75361.